Patent classifications
C07F9/3808
ENHANCING CD8+ T CELLS FOR ADOPTIVE T CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP)
The invention encompasses ex vivo method of stimulating isolated memory T-cell, tumor-infiltrating lymphocyte (TIL), T cell receptor (TCR) engineered cell, and/or chimeric antigen receptor (CAR) engineered cell with compounds of Formula I below, which are inhibitors of the TC-PTP enzyme.
##STR00001##
Biological buffers with wide buffering ranges
Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.
Phosphorus functional antimicrobial coatings for metal surfaces
The invention relates to quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds, processes for preparing quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds, antimicrobial coating compositions comprising quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds and method of treating a surface with said compositions to provide a durable, antimicrobial-treated surface.
ANTIBACTERIAL COMPOUNDS
The present invention relates to certain compounds of formula (I) wherein—Ar is (Ar1) or (Ar2) and to their uses as antibacterial agents. The invention further relates to methods of treatment of bacterial infection with such compounds, optionally in combination with other antimicrobials and to compositions and pharmaceutical formulations containing such compounds. The invention additionally relates to coatings containing such compounds and to items having such coatings.
##STR00001##
NOVEL PEROXIDE STABILIZERS
Methods for stabilizing one or more peroxide compounds in solution comprising adding to the solution an effective amount of at least one compound selected from the group comprising (i) cyclic carbonates; (ii) poly-phosphonic acid chelating agents and salts thereof, and alkaline pH adjusting agents with a pKb value of up to 3.0, wherein the w/w ratio of the poly-phosphonic acid chelating agent or salt thereof to alkali or alkaline earth metal hydroxide is from about 1:1 to about 50:1; and (iii) mixtures thereof. Also disclosed are solutions comprising the above compounds, uses of the above compounds to stabilize peroxide compounds in solutions, and compounds recited above for use as novel stabilizers.
Biological buffers with wide buffering ranges
Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.
PHOSPHATE DERIVATIVES AND USE THEREOF
The present invention discloses a compound with the following formula (I), or a tautomer, mesomer, racemate, enantiomer, and diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug molecule thereof, wherein D is selected from:
##STR00001##
The invention further discloses the use of the compound in the preparation of drugs for preventing and/or treating cancers, and the use of the compound in the preparation of drugs for inhibiting cancer metastasis. The compound of the present invention can effectively inhibit the proliferation and metastasis of cancer cells by adjusting the acidity of a tumor microenvironment to achieve a better effect in clinical cancer treatment, and has broad application prospects.
##STR00002##
Electronic switching element
An electronic switching element is described having, in sequence, a first electrode, a molecular layer bonded to a substrate, and a second electrode. The molecular layer contains compounds of formula I, R.sup.1-(A.sup.1-Z.sup.1).sub.rB.sup.1(Z.sup.2-A.sup.2).sub.s-Sp-G, wherein A.sup.1, A.sup.2, B.sup.1, Z.sup.1, Z.sup.2, Sp, G, r, and s are as defined herein, in which a mesogenic radical is bonded to the substrate via a spacer group, Sp, by means of an anchor group, G. The switching element is suitable for production of components that can operate as a memristive device for digital information storage.
QUINONES HAVING HIGH CAPACITY RETENTION FOR USE AS ELECTROLYTES IN AQUEOUS REDOX FLOW BATTERIES
We disclose quinone compounds and related species (Formula I) that possess significant advantages when used as a redox active material in a battery, e.g., a redox flow battery. In particular, the compounds provide redox flow batteries (RFBs) with extremely high capacity retention. For example, RFBs of the invention can be cycled for 500 times with negligible loss of capacity, and such batteries could be employed for years of service. Thus, the invention provides a high efficiency, long cycle life redox flow battery with reasonable power cost, low energy cost, and all the energy scaling advantages of a flow battery.
##STR00001##
PHARMACOLOGICAL AGENTS FOR TREATING CONDITIONS OF THE EYE
Provided are compounds useful for treating, preventing, reducing the occurrence of, slowing the progression of, or reducing, ameliorating, or alleviating the symptoms associated with a condition selected from the group consisting of: presbyopia, cataract, transthyretin (TTR)-associated amyloidosis, myopia, or other conditions or disorders associated with the eye, including COMT inhibitors and pro-drugs thereof, and methods of using these compounds.